Related Experiment Videos
Primary biliary cirrhosis and primary sclerosing cholangitis
1Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota, USA.
Clinics in Liver Disease
|April 9, 2001
Summary
Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are chronic cholestatic liver diseases. Ursodeoxycholic acid treats PBC, while PSC lacks disease-modifying therapies, with liver transplantation as a last resort.
Area of Science:
- Hepatology
- Immunology
- Genetics
Background:
- Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are leading causes of chronic cholestatic liver disease in adults.
- These conditions can progress to biliary cirrhosis, portal hypertension, and liver failure.
- Despite advances, the interplay between genetic and immune factors in their pathogenesis remains incompletely understood.
Purpose of the Study:
- To review the current understanding of chronic cholestatic liver diseases, PBC and PSC.
- To discuss current and potential therapeutic strategies.
- To highlight the role of liver transplantation in end-stage disease.
Main Methods:
- Literature review of pathogenesis and treatment of PBC and PSC.
- Analysis of current therapeutic recommendations and ongoing clinical trials.
- Evaluation of liver transplantation as a treatment option.
Main Results:
- Ursodeoxycholic acid (13-15 mg/kg/d) is the only recommended treatment for PBC.
- No specific medical therapy currently halts disease progression in PSC, though agents are under investigation.
- Liver transplantation is the definitive treatment for end-stage PBC and PSC.
Conclusions:
- Effective treatments for PBC and PSC are limited, underscoring the need for further research into pathogenesis.
- Targeted therapies are needed to alter the natural history of PSC.
- Liver transplantation remains crucial for managing advanced disease in both conditions.